Trial Profile
Multi-center Observational Study Relating to the Tolerance of ISENTRESS® + TRUVADA® Prescribed in Post-Exposure Prophylaxis of Persons Recently Subjected to the Risk of Transmission of an HIV Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 22 Feb 2017 Status changed from not yet recruiting to completed.
- 05 May 2010 New trial record